Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of ATB-101 vs. Co-administration of Olmesartan and Dapagliflozin
NCT05017987Phase 1Completed
- Sponsor
- Autotelic Bio
- Start
- Jun 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of olmesartan + dapagliflozin in hypertension (HTN) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Autotelic Bio. Primary endpoints: Area Under the Concentration-time Curve to the Last Measurable Concentration at Day 8 and Maximum Plasma Concentration at Day 8. Started Jun 2021; status: completed.
02
Drugs
olmesartan + dapagliflozin
03
Conditions
hypertension (HTN)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05017987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05017987.